ALP receives grants from NIH, NHLBI, the EU (via the VERDI Consortium), Gilead, ViiV Healthcare, and Merck for commercial drug studies paid to the organisation NEAT ID; receives honoraria for educational talks and advisory board membership from Gilead, ViiV Healthcare, Merck, and Virology Education; is on a data safety monitoring board for MRC–PENTA studies; is a member of the EACS and BHIVA HIV treatment guidelines panels; is the President of NEAT ID; and is a board member of CUAMM UK. WDFV receives grants from the Bill & Melinda Gates Foundation, SA Medical Research Council, NIH, Unitaid, Foundation for Innovative New Diagnostics, Children's Investment Fund Foundation, USAID, ViiV Healthcare, and Merck, paid to the institution; receives drug donations from Gilead, ViiV Healthcare, Merck, and Johnson & Johnson; does commercial drug studies for Merck and Novo; receives honoraria for educational talks and advisory board membership for Gilead, ViiV Healthcare, Mylan–Viatris, Merck, Adcock-Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, and Virology Education; and is a member of the International NIH HIV data safety monitoring board and WHO and SAHCS HIV guideline committees.